CD86 and B-cell chronic lymphocytic leukemia: We also confirmed that CLL cells in aCD3 cultures became activated (11, 12, 27), and favored the upregulation of CD86, PD-1 and PD1-L on CLL cells (Figure 2E) which was impaired by SKI-II and opaganib (Figure 2F).